BCL2 and familial pancreatic carcinoma: Activity of compounds 1–4 against Bcl‐2 family proteins including binding inhibition (IC50) of FITC‐mNoxa to Mcl‐1, binding affinity constant (Ki), and cell growth inhibition (IC50) of pancreatic cancer cells lines MiaPaCa‐2 and BxPC‐3.